About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT06790680

GITMO AML/MDS-Relapse Registry Study

The proposal arises from the increasingly pressing need to have a program of therapy for the prevention of relapse after allogeneic transplantation in patients with acute myeloid leukemia or myelodysp...

Lead sponsor: Gruppo Italiano Trapianto di Midollo Osseo•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Gruppo Italiano Trapianto di Midollo Osseo

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•All patients with AML and MDS who underwent allo-SCT from 2015 to 2021, who relapsed and received salvage therapy for the relapse.

Exclusion Criteria

•Patients with a diagnosis other than AML and MDS transplanted in the same period.

Related studies

RECRUITINGPhase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

NCT03520647 · Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), and more

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, and more

RECRUITINGPhase 1/2

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT06303193 · Myelodysplastic Syndromes

RECRUITINGPhase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, and more

RECRUITINGPhase 2

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867 · Myelodysplastic Syndromes

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 28, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment859

Start dateDec 2022

Last updatedJan 28, 2025

Condition

Acute Myeloid Leukaemia Myelodysplastic Syndrome

Locations shown

GITMO

Bologna, Italy

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions